Blood and lymphatic system disorders – page 72

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Study of Rilzabrutinib for Adults with Relapsed Immune Thrombocytopenia

Study of Rilzabrutinib for Adults with Relapsed Immune Thrombocytopenia

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Long-Term Safety Study of Riliprubart in Patients with Cold Agglutinin Disease

Long-Term Safety Study of Riliprubart in Patients with Cold Agglutinin Disease

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

Study on the Use of Human Normal Immunoglobulin for Preventing Infections in Patients with Chronic Lymphocytic Leukemia and Secondary Immunodeficiency

Study on the Use of Human Normal Immunoglobulin for Preventing Infections in Patients with Chronic Lymphocytic Leukemia and Secondary Immunodeficiency

Study of Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Study of Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Study on the Effects and Safety of Rilzabrutinib for Adults with Warm Autoimmune Hemolytic Anemia

Study on the Effects and Safety of Rilzabrutinib for Adults with Warm Autoimmune Hemolytic Anemia